Catalogs from Navinci Diagnostics
Naveni® Plex – isPLA Multiplex Solution
Uncover complex protein interactions in the tumor microenvironment with Naveni® Plex, the groundbreaking in situ-Proximity Ligation Assay (PLA) multiplex solution designed to simultaneously detect PD1/PD-L1 interactions, PD1/PD-L2 interactions, PD1/SHP-2 interactions, CD8/MHC-I interactions and CD3 presence. Three pairs of primary antibodies conjugated to proprietary oligonucleotide arms (Navenibodies) are simultaneously incubated with your FFPE tissue sample, allowing you to map multiple protein interactions at the same time in the cancer immune interface, going beyond expression to reveal functionality. Updated January 2026.
Naveni® Plex Omni Service – NextGen Spatial Interactomics run by Experts
Explore elusive proteins and functional states with Navinci’s in situ proximity ligation assay (isPLA) multiplexing system. Detect up to eight protein interactions, single proteins, or phosphorylation states simultaneously in human FFPE samples to reveal tumour–stroma crosstalk, immune cell states, and molecular networks driving disease and treatment response. With the Naveni® Plex Omni Service, your samples are analyzed by the experts behind the technology – delivering custom panels, expert-run assays, and seamless end-to-end support so you can focus on discoveries. Released November 2025.
NaveniBright™ BOND RX – Illuminating Function in Spatial Proteomics
Automated detection of protein-protein interactions and post-translational modifications in situ. The NaveniBright™ BOND RX introduces a novel product line, seamlessly integrating chromogenic readout automation on the BOND RX Fully Automated Research Stainer by Leica Biosystems. This kit is meticulously crafted based on Navinci's cutting-edge Naveni® in situ proximity ligation technology, offering flexibility tailored to your unique primary antibodies and targets. With the automated workflow, you will save valuable time, reduce hands-on time and maximize your overall research productivity. Released June 2024.
NaveniFlex™ BOND RX Atto647N/Red
Automated detection of protein-protein interactions and posttranslational modifications in situ: The NaveniFlex BOND RX Atto647N/Red (NAV-60009 & NAV-60010) allows the automation of the Naveni® isPLA with fluorescence readout on the BOND RX/RXm Fully Automated Research Stainer. These in situ kits are meticulously crafted based on our cutting-edge Naveni® in situ proximity ligation technology, offering you the flexibility to use your own primary antibodies to detect your unique targets. Released June 2026.
NaveniBright™ PD1/PD-L1 BOND RX – Automated Detection of PD1/PD-L1 Interactions in situ
Immune checkpoint therapy (ICT) responses can vary among patients, underscoring the need for improved predictive biomarkers to refine patient stratification. Although PD-L1 immunohistochemistry is widely used, the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear. Now, Navinci introduces the NaveniBright™ PD1/PD-L1 BOND RX in collaboration with Leica Biosystems to evaluate the potential of PD1/PD-L1 interaction as a biomarker with a high throughput automated kit. Achieve heightened efficiency and reproducibility through an automated workflow, streamlining your research process. Released June 2024.
Naveni® PD1/PD-L1 BOND RX Atto647N/Red
Successful patient stratification is key for optimizing response to treatment in immune checkpoint inhibition therapy. Naveni® PD1/PD-L1 BOND Atto647N/Red (NAV-60011 & NAV-60012) is the first automated fluorescent assay for in situ detection of PD-1/PD-L1 interactions, enabling deeper immune profiling and insights into protein function and interaction in the tumor microenvironment landscape and signaling pathways. Launched in collaboration with Leica Biosystems, the Naveni® PD1/PD-L1 BOND RX Atto647N/Red offers enhanced reproducibility and throughput. Released June 2026.
Naveni® CD8/MHC-I Atto647N – Navigate Immune Responses in situ
Dive into the secrets of immune responses with Navinci's CD8/MHC-I in situ proximity ligation assay for the detection of CD8/MHC-I interactions, providing a nuanced perspective for a detailed and accurate portrayal of the immune response. This deeper understanding becomes the cornerstone for developing targeted immunotherapies, marking a potential leap forward in precision medicine for cancer treatment. Navinci has now developed the first commercial in situ proximity ligation assay for the specific detection of CD8/MHC-I interactions. Released February 2024.
Naveni® PD1/PD-L1 Atto647N – Illuminate PD1/PD-L1 Interactions
Unlock the potential of immune checkpoint inhibition therapy with the newest product by Navinci: Naveni® PD1/PD-L1 Atto647N, the pioneering fluorescent assay for in situ detection of PD1/PD-L1 interactions. Use this assay to identify PD1/PD-L1 interactions with exceptional specificity and to visualize PD1/PD-L1 in the tumor microenvironment. Enhance the understanding of signaling pathways in the context of immune checkpoint blockade and uncover the diagnostic potential of the PD1/PD-L1 interaction. Released July 2023.
NaveniFlex™ Cell – Elevate Your Research
Since diverse sample types demand tailored treatment, our partner Navinci has optimized their flexible offering, aligning it even more closely with your needs. NaveniFlex™ Cell (NAV-60017 & NAV-60025) is based on the company's Naveni™ proximity ligation technology and is specifically optimized for studying protein-protein interactions and protein interplay in cell samples. It allows you to analyze even the most low-abundance protein targets with high precision and to obtain easily quantifiable data. The protocol is more than 60 minutes faster than the previous kits and it is also compatible with 96-well plates for high throughput screening. Released September 2023.
NaveniFlex™ Tissue – An eye-opening Solution for Tissue Samples
Looking for protein-protein interactions or post-translational modifications in tissues? We’ve got you covered. The advanced Naveni™ proximity ligation technology developed by Navinci for NaveniFlex™ Tissue kits (NAV-60026 & NAV-60027) is tailor-made to overcome common background challenges in tissue samples. The kits are optimized to deliver highly reproducible and accurate results even for the least abundant protein interactions. NaveniFlex™ Tissue is an eye-opening solution for your tissue samples. Released January 2023.
Naveni® Detect + Interact – Discover the Secret Life of Proteins
Ever wished there was a way to take a snapshot of two proteins as they interact or remain unbound? Find out about protein complex formation and disassembly in response to different stimuli in situ with the help of Navinci's latest innovation. Naveni® Detect + Interact (formerly Naveni® TriFlex Cell) is a revolutionary proximity-based technology that can concurrently visualize two proteins in a free and complex state in any cell compartment. It aids you in elucidating the spatiotemporal communication between proteins in their native environment. With Naveni™ TriFlex Cell, you can detect the relative amounts of total protein A, total protein B, and the interaction AB between the two proteins. Understanding the relationship between your favorite proteins has never been easier! Released January 2023.
NaveniLink™ – Expanding your Options
Would you like to conjugate your own primary antibodies for using them in proximity ligation assays? The NaveniLink conjugation kit by Navinci allows you to do just that. You can use your primary antibodies and easily conjugate them with Navinci's proprietary oligonucleotide sequences. These conjugates can be used with the Naveni® flexible product line, which includes NaveniFlex Cell, NaveniFlex Tissue, and NaveniBright. NaveniLink offers a practical solution to enhance your research capabilities. Released April 2023.
NaveniBright™ – Bringing Precision to Spatial Proteomics
In situ detection of protein-protein interactions and post-translational modifications. The NaveniBright™ by Navinci is a Naveni® product line with chromogenic readout. This in situ kit is based on the Naveni® in situ proximity ligation technology. The assay significantly enhances the chromogenic signal, providing you with stronger and more accurate staining of your cell or tissue samples. NaveniBright™ is a secondary detection system to be used with your primary antibodies. The method does not require specialized instrumentation and is compatible with established in situ workflows. Released May 2022.
NaveniBright™ PD1/PD-L1 – Detect PD1/PD-L1 Interactions in situ
Despite the recent success of immune checkpoint inhibitors, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed. PD-L1 IHC is commonly used as a biomarker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear. NaveniBright™ PD1/PD-L1 developed by Navinci is the first commercial Proximity Ligation Assay for the specific in situ detection of PD1/PD-L1 interactions. Released September 2022.